The ability of PPARα activation to improve liver steatosis and steatohepatitis as well as insulin resistance in rodents led to a few small clinical studies to determine the effects of fibrates on NAFLD progression [107,108,109,110,111]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.